Alpha-mannosidosis
al-fuh-man-oh-si-DOH-sis
Also known as: Alpha-mannosidase deficiency, Lysosomal storage disorder
At a Glance
What is Alpha-mannosidosis?
Alpha-mannosidosis is a rare genetic disorder that affects the body's ability to break down certain complex sugars. It primarily impacts the skeletal, immune, and central nervous systems. The condition is caused by mutations in the MAN2B1 gene, leading to a deficiency of the enzyme alpha-mannosidase. Over time, this enzyme deficiency results in the accumulation of sugars in the body's cells, causing progressive damage. Early symptoms may include recurrent infections, distinctive facial features, and developmental delays. As the disease progresses, individuals may experience hearing loss, skeletal abnormalities, and intellectual disability. Early diagnosis is critical to manage symptoms and improve quality of life. The condition can significantly impact family life, requiring ongoing medical care and support. Prognosis varies, with some individuals leading relatively normal lives while others may experience severe complications. Daily life for affected individuals often involves managing physical and cognitive challenges. Treatment options are limited but may include enzyme replacement therapy and supportive care. Research is ongoing to find more effective therapies.
Medical Definition
Alpha-mannosidosis is a lysosomal storage disorder caused by mutations in the MAN2B1 gene, leading to a deficiency of the enzyme alpha-mannosidase. Pathologically, this results in the accumulation of mannose-rich oligosaccharides in lysosomes, causing cellular dysfunction. Histologically, affected tissues show vacuolation due to storage material accumulation. It is classified under lysosomal storage disorders and is inherited in an autosomal recessive pattern. Epidemiologically, it is considered an ultra-rare disease with a prevalence of approximately 1 in 500,000. The disease course is progressive, with symptoms worsening over time if not managed effectively.
Alpha-mannosidosis Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Intellectual disability in alpha-mannosidosis manifests as developmental delays and learning difficulties. This occurs due to the accumulation of mannose-rich oligosaccharides in the central nervous system, affecting neuronal function. Over time, cognitive impairment may become more pronounced, impacting educational and occupational achievements. Early intervention with educational support and therapies can help maximize the individual's potential and improve quality of life.
Hearing loss is often one of the earliest signs of alpha-mannosidosis and can range from mild to profound. It results from recurrent ear infections and structural abnormalities in the ear caused by glycoprotein accumulation. As the disease progresses, hearing loss can worsen, leading to communication difficulties. Hearing aids and regular audiological assessments are crucial for managing this symptom and enhancing communication abilities.
Skeletal abnormalities include joint stiffness, scoliosis, and bone deformities. These occur due to the storage of oligosaccharides in connective tissues, affecting bone growth and joint function. Over time, these abnormalities can lead to mobility issues and chronic pain. Physical therapy and orthopedic interventions can help manage symptoms and improve mobility.
Common
Patients with alpha-mannosidosis often experience recurrent respiratory and ear infections. This is due to immune system dysfunction caused by the accumulation of mannose-rich compounds affecting immune cell function. Over time, frequent infections can lead to chronic respiratory issues and hearing loss. Prophylactic antibiotics and regular monitoring can help reduce the frequency and severity of infections.
Coarse facial features develop as a result of glycoprotein accumulation in facial tissues. This leads to characteristic changes such as a broad nose, thick lips, and an enlarged tongue. These features become more pronounced with age and can affect self-esteem and social interactions. Supportive care and counseling can assist in addressing psychosocial impacts.
Muscle weakness in alpha-mannosidosis is characterized by reduced muscle tone and strength. It is caused by the storage of oligosaccharides in muscle tissues, impairing muscle function. As the disease progresses, muscle weakness can lead to difficulties in physical activities and increased fatigue. Physical therapy and regular exercise can help maintain muscle strength and improve endurance.
Less Common
Hydrocephalus, or fluid accumulation in the brain, can occur in some individuals with alpha-mannosidosis. It results from impaired cerebrospinal fluid circulation due to glycoprotein deposits. If untreated, hydrocephalus can lead to increased intracranial pressure and neurological complications. Surgical intervention, such as shunt placement, may be necessary to manage this condition.
Ataxia presents as uncoordinated movements and balance difficulties in alpha-mannosidosis patients. This symptom arises from the accumulation of storage material affecting the cerebellum and other parts of the nervous system. Over time, ataxia can lead to increased risk of falls and mobility challenges. Rehabilitation therapies, including physical and occupational therapy, can help improve coordination and safety.
What Causes Alpha-mannosidosis?
Alpha-mannosidosis is caused by mutations in the MAN2B1 gene, located on chromosome 19p13.2. The MAN2B1 gene encodes the lysosomal enzyme alpha-mannosidase, which is crucial for the degradation of mannose-rich oligosaccharides. Mutations in MAN2B1 lead to the production of a dysfunctional enzyme, which cannot effectively break down these oligosaccharides. As a result, there is an accumulation of mannose-rich compounds within lysosomes, causing cellular storage dysfunction. This lysosomal storage disorder disrupts normal cellular homeostasis and affects multiple organelles, leading to impaired cellular function. Neighboring cells and tissues are affected due to the buildup of storage material, which can trigger inflammatory responses. Neuroinflammation is a significant consequence, contributing to progressive neurological decline. The accumulation of storage material in the central nervous system leads to white matter degeneration and other structural brain changes. Symptoms appear in a specific pattern due to the progressive nature of storage material accumulation and its impact on different tissues. The variability in disease severity among patients is attributed to the type and location of the mutation within the MAN2B1 gene, as well as other genetic and environmental factors. Patients may experience a range of symptoms, including intellectual disability, hearing loss, and skeletal abnormalities, depending on the extent of enzyme deficiency. The immune response may exacerbate the condition by promoting further tissue damage and inflammation. Over time, the progressive accumulation of storage material leads to widespread organ dysfunction. The pattern of symptom onset and progression is influenced by the differential vulnerability of tissues to storage material accumulation. Genetic modifiers and environmental influences can further modulate the clinical presentation and progression of alpha-mannosidosis.
How is Alpha-mannosidosis Diagnosed?
Typical age of diagnosis: Alpha-mannosidosis is typically diagnosed in early childhood, often between the ages of 1 and 5, when developmental delays and recurrent infections prompt further investigation. Diagnosis may be delayed due to the rarity of the disease and the variability of symptoms. Early recognition is crucial for management and intervention. Genetic counseling is recommended for families once a diagnosis is confirmed.
Clinicians look for developmental delays, recurrent infections, and distinctive facial features. A detailed family history is taken to identify any genetic predisposition. Physical examination may reveal hepatosplenomegaly, skeletal abnormalities, and hearing loss. This step helps to narrow down the differential diagnosis and prioritize further testing.
Magnetic Resonance Imaging (MRI) is often used to assess brain and skeletal abnormalities. MRI may reveal white matter changes and skeletal dysplasia, which are indicative of alpha-mannosidosis. These findings help confirm the diagnosis by correlating clinical symptoms with structural changes. Imaging also helps exclude other conditions with similar presentations, such as mucopolysaccharidoses.
Enzyme assays are ordered to measure alpha-mannosidase activity in leukocytes or fibroblasts. Reduced enzyme activity is a hallmark of the disease. Abnormal results show significantly decreased enzyme levels compared to normal ranges. These results guide the clinician to proceed with genetic testing for definitive diagnosis.
The MAN2B1 gene is sequenced to identify mutations responsible for alpha-mannosidosis. Common mutations include missense, nonsense, and splice-site mutations. Genetic testing confirms the diagnosis by identifying pathogenic variants. Results are crucial for family counseling and assessing the risk of recurrence in future pregnancies.
Alpha-mannosidosis Treatment Options
Enzyme replacement therapy (ERT) involves the administration of recombinant human alpha-mannosidase. The mechanism of action is to supplement the deficient enzyme, thereby reducing lysosomal storage. Velmanase alfa is a specific drug used in clinical practice. Clinical trials have shown improvement in biochemical markers and some clinical symptoms. Limitations include the need for lifelong treatment and potential infusion-related reactions.
Techniques include range-of-motion exercises, strength training, and balance activities. The goal is to improve mobility, reduce joint stiffness, and enhance overall physical function. Sessions are typically conducted 2-3 times per week, lasting about an hour each. Measurable outcomes include improved gait and increased muscle strength. Long-term benefits include enhanced quality of life and reduced risk of secondary complications.
Surgery is indicated for patients with significant hearing loss unresponsive to conventional aids. The procedure involves the implantation of a cochlear device to improve auditory function. Expected benefits include improved hearing and communication abilities. Surgical risks include infection and device failure. Post-operative care involves regular audiological assessments and device adjustments.
The care team typically includes geneticists, neurologists, audiologists, and physical therapists. Interventions focus on managing symptoms, improving quality of life, and providing psychosocial support. Strategies include regular follow-ups, counseling, and educational support for families. Family education is crucial for understanding the disease and managing expectations. Long-term monitoring involves periodic assessments to adjust care plans as needed.
When to See a Doctor for Alpha-mannosidosis
- Severe respiratory distress — this is an emergency because it can indicate a life-threatening airway obstruction or infection.
- Sudden loss of consciousness — this could be a sign of a serious neurological event requiring immediate medical attention.
- Acute swelling of the face or throat — this may suggest an allergic reaction or other critical condition that can rapidly compromise breathing.
- Progressive hearing loss — significant as it can affect communication and quality of life; consult an audiologist.
- Frequent infections — may indicate immune system involvement; seek advice from an immunologist.
- Worsening mobility issues — important to address early to prevent further decline; consider seeing a physiotherapist.
- Mild fatigue — monitor energy levels and ensure adequate rest; if persistent, discuss with a healthcare provider.
- Occasional joint pain — track pain episodes and manage with over-the-counter analgesics; consult a doctor if it worsens.
Alpha-mannosidosis — Frequently Asked Questions
Is this condition hereditary?
Alpha-mannosidosis is inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell have mutations. Parents of an individual with alpha-mannosidosis are carriers and typically do not show symptoms. De novo mutations are rare in this condition. Carrier status can be determined through genetic testing, which is important for family planning. Genetic counseling is recommended for affected families to understand inheritance patterns and risks.
What is the life expectancy for someone with this condition?
Life expectancy varies based on the severity and age of onset of alpha-mannosidosis. Early-onset cases tend to have a poorer prognosis due to rapid disease progression. Mortality is often due to complications such as infections or neurological decline. Treatment, including enzyme replacement therapy, can improve survival and quality of life. Realistic expectations should include regular monitoring and supportive care to manage symptoms.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis involves a combination of clinical evaluation, biochemical tests, and genetic testing. The time from first symptoms to diagnosis can vary, often taking several years due to the rarity of the condition. Specialists such as geneticists, neurologists, and metabolic experts are typically involved. Delays in diagnosis are common due to symptom overlap with other conditions. Confirmation is achieved through enzyme assays and genetic testing.
Are there any new treatments or clinical trials available?
Current research is exploring enzyme replacement therapy and gene therapy as promising treatments for alpha-mannosidosis. Novel approaches aim to address the underlying genetic cause of the disease. Clinical trials can be found on ClinicalTrials.gov by searching for alpha-mannosidosis. Patients should discuss potential trial participation with their healthcare provider. New treatments may become available in the next few years, but timelines are uncertain.
How does this condition affect daily life and activities?
Alpha-mannosidosis can impact mobility, requiring physical therapy and adaptive devices for self-care. Educational challenges may arise due to cognitive impairments, necessitating special education services. Social and emotional challenges are common, affecting both patients and families. The condition can place a significant burden on families, requiring comprehensive support. Adaptations such as assistive technology and community resources can greatly enhance quality of life.
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Alpha-Mannosidosis: Therapeutic Strategies.
Ceccarini MR, Codini M, Conte C et al. · Int J Mol Sci · 2018 · PMID: 29772816
- 2.Alpha-Mannosidosis.
Adam MP, Bick S, Mirzaa GM et al. · Unknown Journal · 1993 · PMID: 20301570
- 3.Alpha-mannosidosis.
Malm D, Nilssen Ø · Orphanet J Rare Dis · 2008 · PMID: 18651971
- 4.[Alpha-mannosidosis].
Hennermann JB · MMW Fortschr Med · 2026 · PMID: 41699219
- 5.Lysosomal alpha-mannosidase and alpha-mannosidosis.
Paciotti S, Codini M, Tasegian A et al. · Front Biosci (Landmark Ed) · 2017 · PMID: 27814608
- 6.Diagnosis of alpha-Mannosidosis: Practical approaches to reducing diagnostic delays in this ultra-rare disease.
Santoro L, Cefalo G, Canalini F et al. · Mol Genet Metab · 2024 · PMID: 38555683
- 7.[Alpha-mannosidosis].
Yamaguchi S · Ryoikibetsu Shokogun Shirizu · 1998 · PMID: 9645108
- 8.Intellectual functioning in alpha-mannosidosis.
Cathey SS, Sarasua SM, Simensen R et al. · JIMD Rep · 2019 · PMID: 31741826
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-04-25